Navigation Links
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Date:11/10/2008

Company Will Host a Conference Call Today To Discuss the Data and Ongoing

Clinical Development Programs

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in a number of measures of nerve function and health at the primary analysis point, day 180 post-treatment.

Sangamo management will host a conference call at 5:00 p.m. ET today to review these data and the ongoing clinical studies supporting the development of SB-509.

"Our first Phase 2 study, SB-509-601, had three goals," stated Dale Ando, M.D., Sangamo's vice president, therapeutic development and CMO. "First, we wanted to determine the safety of repeat dosing. Second, we evaluated dose schedule, specifically whether a regimen of three administrations of the maximum dose given at two month intervals would be more effective than a single administration. Finally, we hoped to gain clarity around clinical endpoints for use in the design of future studies. While this study has not added to our data around the most suitable end-points or dosing schedule for a Phase 3 trial, it has demonstrated that the drug continues to have an excellent safety profile. This is valuable information for our future development efforts."

"We also know that SB-509 is an active agent. We have positive preclinical dat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
2. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
5. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
6. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
8. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
9. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
10. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
11. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript’s trade secrets, and that it improperly ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... could be a shot in the arm for adoptive ... and controlling the growth of T cells in living ... of the therapy,s drawbacks. The engineers altered the ... which researchers can build new functions into cells by ...
... ATHENS, Ohio (April 26, 2010) Though scientists argue ... electronics for building the next generation of faster, smaller, ... actually seen the spina quantum mechanical property of electronsin ... an Advance Online Publication in the journal Nature ...
... ... 2010 Growth , ... Chicago, IL (Vocus) April 26, 2010 -- Sword Diagnostics, Inc. , committed to ... its corporate headquarters and research facilities to accommodate planned growth. Double the size of ...
Cached Biology Technology:New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 2New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 3Physicists capture first images of atomic spin 2Life Sciences Company Sword Diagnostics Moves Operations to Chicago 2Life Sciences Company Sword Diagnostics Moves Operations to Chicago 3
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... has hit pay dirt for Case Western Reserve University ... The researchers have created a line of patented ... that can take on the shape and size of ... trays to rubber ducky molds to clam-shell packaging molds ...
... "family tree" of genes expressed in one form of ... at the U.S. Department of Energy,s Brookhaven National Laboratory ... more amenable to biofuel production. The study, published in ... , also lays a foundation for understanding these genes, ...
... the University of Gothenburg and Stockholm University discovered a new ... radicans , evolved from a bladder wrack (Fucus vesiculosus) ancestor ... show that, from an evolutionary perspective, it was formed ... ago, and probably as recently as about 400 years ago. ...
Cached Biology News:Case Western Reserve University engineers hit pay dirt with clay mixture 2Case Western Reserve University engineers hit pay dirt with clay mixture 3Plant gene mapping may lead to better biofuel production 2
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Biology Products: